News
EXAI
4.150
-4.82%
-0.210
Weekly Report: what happened at EXAI last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at EXAI last week (0401-0405)?
Weekly Report · 04/08 09:08
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. The company reportedly issued a weak outlook at the J.P. Morgan Retail Roundup investor conference. ARCA biopharma, Inc. Shares climbed 108% in the mid-day session.
Benzinga · 04/03 17:56
Weekly Report: what happened at EXAI last week (0325-0329)?
Weekly Report · 04/01 09:07
Weekly Report: what happened at EXAI last week (0318-0322)?
Weekly Report · 03/25 09:07
Analysts’ Top Healthcare Picks: Healthequity (HQY), Exscientia Plc (EXAI)
TipRanks · 03/22 07:40
32 “Breakthroughs” stocks by BofA - Part 2
Tech 32 “Breakthroughs” stocks by BofA Securities published a list of 32 companies that its analysts believe will benefit from breakthroughs. These 32 stocks have a combined market cap of $16T. The list includes companies in the healthcare, communications, and energy sectors.
Seeking Alpha · 03/21 15:53
Exscientia files for $300M mixed shelf offering
Seeking Alpha · 03/21 15:12
Exscientia Plc Files For Mixed Shelf Of Up To $300M
Benzinga · 03/21 13:25
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The company's market cap is at $5.2 billion. Immunovant and argenx stock moved upwards by 14.0% and 13.24% respectively. Losers Tourmaline Bio and Avinger stock decreased by 33.4% during the pre- market session.
Benzinga · 03/21 13:05
Exscientia Plc Reports Progressive Drug Pipeline
Exscientia Plc, a leader in AI-powered drug design, reported progress in its drug development pipeline for 2023. The company is preparing to progress its CDK7 inhibitor and LSD1 inhibitor through clinical trials. Exscientia remains financially stable with sufficient funds to operate well into 2026.
TipRanks · 03/21 12:57
BILI, EXAI and ENVB among pre-market losers
Destination XL Group DXLG -16% after Q4 earnings release. Tourmaline Bio (TRML) among pre-market losers. BILI, EXAI and ENVB among pre -market losers in the biotech sector. Paltalk, ANGH, TRML, WORX, PYXS, TGL and ANGH are also on the move.
Seeking Alpha · 03/21 12:43
Earnings Scheduled For March 21, 2024
Creative Realities is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Welltower is likely to report earnings for its fourth quarter. Accenture is also projected to report before the bell. Other companies expected to be reporting before the Bell include Shoe Carnival, Y.M.C. And Y.T.
Benzinga · 03/21 10:15
Pre-Market Earnings Report for March 21, 2024 : ACN, APYX, ASO, CCLD, CMC, DBI, DRI, EXAI, FDS, FENC, GAMB, INKT
NASDAQ · 03/20 20:00
Exscientia FY 2023 Earnings Preview
Seeking Alpha · 03/20 15:43
Weekly Report: what happened at EXAI last week (0311-0315)?
Weekly Report · 03/18 09:07
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
Exscientia plc will report financial results for the fourth quarter and full year ended December 31, 2023, on March 21, 2024. The Company will host a conference call and webcast to provide a business update and review financial results. Exscientia is an AI-driven precision medicine company.
Barchart · 03/14 06:00
High conviction stocks with U.S. productivity opportunities due to AI - MS
Morgan Stanley listed high conviction stocks with U.S. Productivity opportunities due to artificial intelligence. Analysts say companies are in the 'experimental' phase of AI, but will start to benefit from it in 2024. The company listed companies that are early adopters of the technology and could see great changes in productivity.
Seeking Alpha · 03/12 19:08
Weekly Report: what happened at EXAI last week (0304-0308)?
Weekly Report · 03/11 09:07
Exscientia plc's (NASDAQ:EXAI) market cap dropped US$139m last week; individual investors who hold 48% were hit as were institutions
A total of 16 investors have a majority stake in Exscientia plc with 50% of the company. The company is not owned by institutions and is mainly owned by individual investors. Insiders own 16% of Ex scientistia and the company has a total of US$751m in shares. The group of 16 has a majority of shares in the company, and owns 48% of it. Ex Scientistia has seen a 16% drop in its share price in the last few days. It's important to understand the different types of shareholders in Ex scientista.
Simply Wall St · 03/05 11:15
More
Webull provides a variety of real-time EXAI stock news. You can receive the latest news about Exscientia Plc through multiple platforms. This information may help you make smarter investment decisions.
About EXAI
Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Precision Target, Precision Design, Precision Experiment, Precision Medicine, Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.